Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed by pathology as gastrointestinal carcinoma and no previous FOLFOX or FOLFIRI based regimen chemotherapy history.~* Female.~* Adult patients ( ≥ 18, ≤ 50 years of age)~* No long-term or excessive alcohol intake history:1.Alcohol intake less than 5 times per week; 2.Alcohol intake less than 100g per day.~* Performance status ECOG 0-1~* Adequate haematological, hepatic, renal and metabolic function parameters:~Leukocytes : 3,500-10,000/mm3, ANC ≥ 1,500/mm3, Platelets ≥ 90,000/mm3, Hb \> 9g/dl (may be transfused or treated with erythropoietin to maintain or exceed this level), Serum creatinine ≤ 1 x upper limit of normal, Bilirubin ≤ 1.5 x upper limit of normal, Serum AST, ALT, ALP ≤ 2.5 x upper limit of normal in absence of liver metastases, or ≤ 5 x upper limit of normal in presence of liver metastases.~* Negative pregnancy test. If pregnancy test were positive, subject should be included in the trial only when the subsequent pregnancy test is negative.~* Ability of reading, comprehending and finishing trial questionnaires and record, including VAS (Visual Analogue Scale) question.~* Before subject registration, written informed consent must be given according to local regulations.~Exclusion Criteria:~* Pregnant women without morning sickness.~* Presence of gastrointestinal tract obstruction or electrolyte imbalance.~* Any history of central nervous system disease(e.g. Primary brain tumour, seizure not controlled with standard medical therapy, brain metastases or history of stroke).~* Contraindication of glucocorticoid:1.Infection of virus, bacteria or fungus uncontrolled by antibiotics; 2.Active stomach or duodenum ulcer; 3.Severe hypertension, atherosclerosis, diabetes; 4.Osteoporosis;5.Corneal ulcer; 6.Pregnancy; 7.Reparative phase of trauma, operation or fraction; 8.Hypercortisolism; 9.Severe mental disorder or epilepsy; 10.Inadequate cardiac or renal function.~* Mental disability or severe emotional or mental disorder.~* Active infection(e.g. pneumonia, hepatitis) or any uncontrolled disease(e.g.diabetic ketoacidosis) that may affect study outcome or expose patients to unnecessary risk.~* Usage of any illicit drug, including medical marijuana or alcohol abusing(China drug dependence criteria).~* Treatment of unapproved medicine in the previous 4 weeks.~* Concomitant therapy of psychotropic medicine such as olanzapine.~* Hypersensitivity history towards Aprepitant, 5-HT3 receptor antagonist or dexamethasone.~* Previous treatment of Aprepitant.~* Unable to swallow capsules.~* Main researchers considered that the patient is unsuited to the trial.~* Unable or unwilling to follow research programme.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Palonosetron/Dexamethasone/Aprepitant (Type: EXPERIMENTAL): None
- Palonosetron/Dexamethasone/Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).